CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of SYH2072, a Class 1 new chemical aldosterone synthase inhibitor tablet for uncontrolled hypertension and primary aldosteronism. The highly selective drug has shown in pre-clinical studies that it can significantly reduce plasma aldosterone and blood pressure without affecting cortisol levels, and with favorable pharmacokinetics and safety, CSPC believes it could become a best-in-class therapy for conditions with substantial unmet clinical need; the company has also filed multiple patent applications in China and overseas, underscoring its push to strengthen its innovative cardiovascular portfolio and competitive position in this high-value segment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.